Single and dual agonists The fundamental difference between these two molecules is that semaglutide is a GLP-1 agonist, i.e., it has a strong structural similarity (95%) with this hormone and specifically activates its receptor, while tirzepatide is a dual agonist, i.e., it has a hybrid structure that allows it to activate both GLP-1 and GIP receptors (Figure 2)
Overall the results of this study, which followed over 200,000 people with diabetes who were treated with GLP1RAs and compared them to over 1.5 million people on other forms of diabetes treatment, is reassuring regarding the risk/benefit ratio for the long term use of GLP1RAs in people with diabetes
Typically, DPP-4 inhibitors are well-tolerated
A decline in estrogen levels after menopause contributes to an increase in heart attack and stroke risk
10.1152/ajpendo.00422.2013 14 LaiL.LeoneT
Participants taking semaglutide demonstrated a 26% reduction in the composite endpoint of heart attack, stroke, or cardiovascular death compared to placeboindependent outcomes that correlate with improved lipid profiles